Publications by authors named "J G Raimann"
Article Synopsis
- Hyperphosphatemia is common in peritoneal dialysis (PD) patients and can lead to poor health outcomes; researchers explored whether weekly creatinine clearance (CrCl) is a better indicator of serum phosphate levels compared to urea clearance.
- A study analyzed data from 16,796 PD patients across several institutions in North and South America, adjusting for various factors like age and gender, to determine the relationship between serum phosphate levels and both CrCl and urea Kt/V.
- The findings indicated that while CrCl did not outperform urea Kt/V in predicting serum phosphate levels, incorporating CrCl into predictive models improved their overall accuracy, suggesting its importance in managing phosphate levels in PD patients.
Collaboration improves multiple academic and social outcomes. Accordingly, computer-supported collaborative learning (CSCL) can be beneficial in distance education contexts to overcome the issues specific to online learning (e.g.
View Article and Find Full Text PDFIndividuals afflicted with advanced kidney dysfunction who require dialysis for medical management exhibit different degrees of native kidney function, called residual kidney function (RKF), ranging from nil to appreciable levels. The primary focus of this manuscript is to delve into the concept of RKF, a pivotal yet under-represented topic in nephrology. To begin, we unpack the definition and intrinsic nature of RKF.
View Article and Find Full Text PDFBackground: Most patients starting chronic in-center hemodialysis (HD) receive conventional hemodialysis (CHD) with three sessions per week targeting specific biochemical clearance. Observational studies suggest that patients with residual kidney function can safely be treated with incremental prescriptions of HD, starting with less frequent sessions and later adjusting to thrice-weekly HD. This trial aims to show objectively that clinically matched incremental HD (CMIHD) is non-inferior to CHD in eligible patients.
View Article and Find Full Text PDFKey Points: We conducted a randomized controlled pilot trial in patients on hemodialysis using a physiology-based individualized anemia therapy assistance software. Patients in the group receiving erythropoiesis-stimulating agent dose recommendations from the novel software showed improvement in hemoglobin stability and erythropoiesis-stimulating agent utilization.
Background: Anemia is common among patients on hemodialysis.